- 作者：W.K. de Jong ; M.J.A. de Jonge ; A.H.D. van der Leest ; J.P. van Meerbeeck ; H.J.M. Groen
- 关键词：Small-cell lung cancer ; Limited-disease ; Phase I study ; Irinotecan ; Cisplatin ; Concurrent thoracic radiotherapy
- 刊名：Lung Cancer
- 出版年：2008
- 出版时间：July 2008
- 年：2008
- 卷：61
- 期：1
- 页码：123-128
- 全文大小：138 K
Results
All patients were evaluable for toxicity and 34 for response. The overall response rate was 67 % (CR: 26 % ; PR: 41 % ; intention-to-treat analysis) (95 % CI: 53.0–84.2 % ). After a median follow-up period of 15 months, the median survival time was 15 months, the median time to tumor progression 8.3 months and the 1-year survival rate 53.8 % . Grade 3/4 neutropenia occurred in 39 % and 36 % of patients receiving EP and PP regimens, respectively. The incidence of febrile neutropenia was 5 % and 3 % for EP and PP regimens, respectively. Other hematologic and non-hematologic toxicities were mild, with the exception of esophagitis occuring in 36 % of patients during and/or immediately after radiotherapy.
Conclusion
Consolidation therapy with PP after sequential EP and thoracic radiotherapy is feasible and well-tolerated; however, the efficacy results are comparable with those previously obtained in the same patients’ population using a combination of EP and TRT.